Clinical Trial Search

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002

Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale

Primary: Epidemiologic Factors Associated With Prevalent Reflux Disease. — 17.6 percentage of participants with GERD

Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day

Primary: Elimination of Moderate-severe Regurgitation at 6 Months — 10; 42 Participants

Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes

Primary: Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19 — 97.37; 93.94; 100.00; 100.00 Percentage of participants…

Primary: Number of Gastroesophageal Refluxes — 42.4 refluxes — p=0.000002

Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change

Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Presence of Reflux in Patients With Polyposis — 15 participants